MedPath

Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozi

Not Applicable
Completed
Conditions
<tr><td>Albuminuria in patients with type 2 diabetes mellitus</td></tr>
Type 2 diabetes mellitus, albuminuria, SGLT2 inhibitor, decentralized
10012653
Registration Number
NL-OMON26308
Lead Sponsor
niversity Medical Center Groningen (UMCG)
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

|
- Leeftijd = 18 jaar |

Exclusion Criteria

|
- Diagnose type 1 diabetes |

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath